Type-2 Diabetes (T2D) affects over 350 million people, and current trends put that number over half a billion within 20 years. Clearly this is a space where therapeutic advancements are needed to alleviate both its suffers, and the burden that it places on national health care systems. Recent additions to the literature surrounding T2D make tremendous progress in both elucidating the molecular mechanisms of the disease, and identifying an actionable therapeutic approach that could be available to patients in the near future.
Read More
Regenerative medicine: exciting, but still in its infancy
My Type 1 diabetes invades every corner of my life. I hate it. While I am incredibly fortunate to live in a time of tremendous technological advancement, lucky to have quality healthcare, and grateful that I have a manageable disease, I still hate it. I want nothing more than a cure, but will I ever be delivered the cure I’ve been promised by clinicians for so many years?
Read MoreRegenerative Medicine on the Doorstep: a technology in its infancy takes another step toward the clinic
In vitro maturation of stem cells into pancreatic β-cells (insulin secreting cells) for implantation into patients with type-1 diabetes (T1D) presents an opportunity for regenerative therapies to expand their usefulness and break into mainstream medicine by treating large patient cohorts.
Read More
